Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). It comes as an aerosol with an inhaler device. You ...

(RTTNews) - AstraZeneca Plc (AZN.L) said the company's Bevespi Aerosphere has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary ...

A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

The future of AstraZeneca’s three-in-one inhaler Breztri, which was previously hit with a surprising FDA rejection, was hinging on the outcome of another phase 3 trial. And the results from that trial ...

March 18 (Reuters) - Drugmaker AstraZeneca (AZN.L), opens new tab said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, ...

AstraZeneca (NASDAQ:AZN) plans to cap out-of-pocket costs for its inhaler medications at $35 per month following Congressional criticism of the company's pricing of the products in the US. The cap, ...

AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.

(RTTNews) - AstraZeneca Plc (AZN.L) said the company's Bevespi Aerosphere has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary ...